Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for inactive non-infectious intermediate, posterior, or pan-uveitis
NL-OMON39341Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Feb 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in noninfectious uveitis (NIU), Hyalitis, posterior uveitis and 1 more comparing Adalimumab with Placebo (2 arms). Primary endpoint: Time to Treatment Failure. Started Feb 2011; status: active, not recruiting.
02
Drugs
03
Conditions
noninfectious uveitis (NIU)Hyalitisposterior uveitisuveitis
Beyond the preview
Go deeper on NL-OMON39341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39341.